羚锐制药：子公司银谷制药苯环喹溴铵鼻喷雾剂新增感冒适应症

Core Viewpoint - Lingrui Pharmaceutical's subsidiary, Yingu Pharmaceutical, has received approval from the National Medical Products Administration for the new indication of phenylpropanolamine nasal spray to treat cold symptoms, enhancing its market position in the nasal medication sector [1] Group 1: Product Development - The phenylpropanolamine nasal spray is now approved for alleviating symptoms such as runny nose, nasal congestion, nasal itching, and sneezing caused by colds [1] - Previously, the product was approved for treating symptoms related to allergic rhinitis and is included in the "Chinese Guidelines for Diagnosis and Treatment of Allergic Rhinitis" [1] - This nasal spray is the only approved anticholinergic nasal medication for allergic rhinitis in China, with a market size of approximately 5.4 billion yuan [1] Group 2: Market Impact - The new indication for cold symptoms positions the product as the first M receptor antagonist nasal spray for post-cold nasal symptoms in China, which is expected to enhance its product strength [1] - Cumulative research and development investment for this product has reached approximately 35.97 million yuan [1]